Jonas Bergh

18PUBLICATIONS
139CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyCancer geneticsBusiness process management
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Apr 08, 2026
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.

Alexios Matikas, Evangelos Tzoras, Michail Sarafidis

|Jul 02, 2025
CYP2D6 genotype and outcome in tamoxifen treated early breast cancer.

Linda Thorén, Jonatan D Lindh, Espen Molden

|Sep 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick

|Jul 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.

Alexios Matikas, Volker Möbus, Richard Greil

Pageof 3